Dynamic immune response and its influencing factors in COVID-19 patients with non-alcoholic fatty liver disease: A cohort study

Figure 4 Impact of liver fibrosis on lymphocyte subsets and their percentages in coronavirus disease 2019 patients with non-alcoholic fatty liver disease: A longitudinal analysis from hospital admission to 4 weeks post-discharge. < F2: Non-significant liver fibrosis; ≥ F2: Significant liver fibrosis; ≥ F4: Cirrhosis. A: Lymphocyte subset counts (cells/μL); B: Lymphocyte subset percentages (%). ^aP < 0.05, < F2 vs ≥ F2; ^bP < 0.05, ≥ F2 vs ≥ F4; ^cP < 0.05, < F2 vs ≥ F4; ^dP < 0.05; ^eP < 0.01; ^fP < 0.001. LY: Lymphocyte counts.